Special Issue

Molecular and Cellular Studies of Natural Compounds as Potential Therapeutics in Basal Ganglia Disorders

Message from the Guest Editors

Basal ganglia disorders are characterized by the presence of abnormal movements, psychiatric symptoms and different degrees of cognitive impairment. Scientific evidence demonstrates that increased output of the basal ganglia inhibits thalamocortical projection neurons, leading to increased inhibition of the ventral anterior and ventral lateral thalamocortical projection neurons, with the subsequent inability to initiate voluntary movement. These disorders are known as hypokinetic disorders and include Parkinson's disease. The molecular and cellular mechanisms for abnormal increases or decreases in basal ganglia output are not yet well understood. However, a variety of molecular alterations have been reported in the pathogenesis of basal ganglia disorders including toxic aggregate formation, transcriptional dysregulation, et al. This Special Issue has the aim to summarize the state of the art and the latest findings published in the field of basal ganglia disorders, as well as elucidating future directions to discover novel natural compounds as potential therapeutics for the treatment of these disorders.

Guest Editors

Dr. Letizia Pruccoli

Department for Life Quality Studies, University of Bologna, 40126 Bologna, Italy

Prof. Dr. Andrea Tarozzi

Department for Life Quality Studies, University of Bologna, 40126 Bologna, Italy

Deadline for manuscript submissions

closed (31 December 2022)

Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed

mdpi.com/si/117913

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals

Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed

mdpi.com/journal/pharmaceuticals

About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.
We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter
Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

MDPI